Welcome to our dedicated page for Tivic Health Systems SEC filings (Ticker: TIVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tivic Health Systems, Inc. (TIVC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Tivic files a range of reports with the U.S. Securities and Exchange Commission that outline its immunotherapeutics strategy, licensing agreements, financings and governance matters.
Investors can review Tivic’s current reports on Form 8‑K, which describe material events such as the exclusive license and amended and restated license agreement for the TLR5 agonist programs Entolimod and Entolasta, the transfer of investigational new drug applications (INDs) for Entolimod, and the acquisition of contract development and manufacturing organization (CDMO) assets used to form Velocity Bioworks. Other 8‑K filings detail executive employment agreements, equity incentive plan amendments, transfer agent changes and shareholder meeting results.
Registration statements like the S‑1/A shed light on Tivic’s status as an emerging growth and smaller reporting company, the registration of common stock and warrants held by selling stockholders, and the structure of preferred stock and convertible securities. These documents help explain how Tivic raises capital to support its biologics and bioelectronic programs.
On this page, Stock Titan surfaces Tivic’s 10‑K annual reports and 10‑Q quarterly reports when available, which typically include risk factors, management’s discussion and analysis, and detailed descriptions of the company’s dual‑platform strategy in biologics and bioelectronic medicine. Form 4 and related ownership filings, when present, can be used to monitor insider equity transactions and incentive awards tied to Tivic’s equity plans.
Stock Titan enhances Tivic’s filings with AI-generated summaries that highlight key terms in license agreements, financing structures, and manufacturing commitments, helping readers quickly identify items such as Entolimod development milestones, Velocity Bioworks obligations, and voting outcomes from shareholder meetings. Real-time EDGAR updates ensure that new Tivic filings appear promptly, while structured views make it easier to navigate between 8‑K events, registration statements and periodic reports for a more complete understanding of TIVC’s regulatory and corporate history.
Tivic Health Systems, Inc. filed a current report to note that it has made a corporate presentation available to investors on its website as of January 20, 2026. The presentation, dated January 2026, is included as Exhibit 99.1 and is provided under Regulation FD, which is intended to ensure fair public disclosure of material information.
The company explains that this investor presentation and the related disclosure are being "furnished" rather than "filed," meaning they are not subject to certain legal liabilities under the Securities Exchange Act and will not be automatically incorporated into other securities filings unless specifically referenced. The report also includes standard cautionary language about forward-looking statements, emphasizing that actual results may differ materially due to various risks and uncertainties described in Tivic Health’s filings with the SEC.
Tivic Health Systems is calling a virtual special stockholder meeting on February 19, 2026 to vote on four proposals tied to recent financings. Stockholders are being asked to approve, under Nasdaq Listing Rule 5635(d), large potential issuances of common stock upon conversion of Series C preferred stock and related warrants, a senior secured convertible note and warrant held by 3i, and Series B preferred stock and related warrants now held by 3i. As of December 29, 2025, Tivic had 2,525,778 common shares outstanding.
The Series C financing could allow issuance of up to 207,692,305 common shares on conversion of Series C preferred, plus 90,135,297 shares on warrant exercise, which the company states would dilute current holders’ ownership to about 0.59%. The Note could convert into up to 52,093,421 shares at the floor price, plus 4,553,213 warrant shares, and the amended Series B structure lowers the conversion floor to $0.39, increasing potential share issuance. A fourth proposal would permit adjournment of the meeting to solicit more votes. The board unanimously recommends voting “FOR” all proposals.
Tivic Health Systems, Inc. has filed a prospectus supplement covering the potential resale of up to 1,580,437 shares of its common stock. These shares consist of stock issuable to 3i, LP upon conversion of Series B Non-Voting Convertible Preferred Stock and exercise of Investor Warrants related to the Fourth Tranche, plus shares issuable upon exercise of Placement Agent Warrants held by Craft Capital designees. The supplement also reflects the assignment of the original Securities Purchase Agreement from Helena Global Investment Opportunities 1 Ltd. to 3i and an amendment to that agreement.
The document updates the selling stockholder table and notes that, as of December 8, 2025, Tivic had 1,765,952 shares of common stock outstanding. It also explains Beneficial Ownership Limitations that generally cap 3i at 4.9% and certain warrant holders at 4.99% of outstanding shares, with the ability to increase these caps to up to 19.9% or 19.99% after 61 days’ notice.
Tivic Health Systems agreed through its subsidiary Velocity Bioworks to buy substantially all assets of Scorpius Holdings’ CDMO business in an Article 9 auction for $16,253,147.10 in cash, assuming no pre‑closing liabilities. The deal closed on December 10, 2025 and moves manufacturing of Tivic’s Entolimod program in‑house while positioning the company to offer contract development and manufacturing services to other clients.
To fund the purchase, Tivic issued to 3i, LP a senior secured convertible note with a principal amount of $16,253,147.10 and a warrant for up to 4,553,213 common shares at a $2.2310 exercise price, together subject to a 19.99% exchange cap equal to 353,013 shares. Tivic also arranged a Series C Non‑Voting Convertible Preferred Stock program of up to 75,000 shares at $1,000 each, for potential gross proceeds of $75,000,000 in multiple tranches, with 6% cumulative dividends, a $2.2310 fixed conversion price and a variable formula with a $0.39 floor, plus additional warrants. The company terminated a prior $25,000,000 equity purchase agreement with Mast Hill and granted new investors participation rights, financing restrictions and, under certain cash burn conditions, board appointment rights.
Tivic Health Systems, Inc. reported that it secured a Techwatch meeting with the Biomedical Advanced Research and Development Authority’s Radiological and Nuclear Medical Countermeasures Program staff to present clinical data on Entolimod’s effects on radiation-induced injury and acute radiation syndrome.
The company also plans to discuss its progress on manufacturing readiness and preparations for a biologics license application, as described in a press release furnished as an exhibit. The report emphasizes that these plans and expectations are forward-looking and subject to significant risks and uncertainties that could cause actual results to differ materially.
Tivic Health Systems (TIVC) filed an 8-K announcing it issued a press release reporting findings from its Clinical Optimization Study for its non-invasive vagus nerve stimulation device. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The filing includes customary forward-looking statements language, noting risks and uncertainties that could cause actual results to differ from expectations.
Tivic Health Systems (TIVC) filed a 424(b)(3) prospectus covering the resale of up to 1,580,437 shares of common stock by selling stockholders. The registered shares comprise up to 1,352,395 shares issuable upon conversion of Fourth Tranche Series B Non‑Voting Convertible Preferred (based on the $1.294 Floor Price), up to 195,793 shares issuable upon exercise of Investor Warrants, and up to 32,249 shares issuable upon exercise of Placement Agent Warrants.
The company is not selling shares in this prospectus and will not receive proceeds from shareholder resales; it would receive cash only upon any warrant exercises. Sales may occur via market or private transactions, including short sales after the registration statement is declared effective. Beneficial ownership is capped at 4.9% (Helena) or 4.99% (placement agent holders), adjustable up to 19.9%/19.99% with 61 days’ notice. Shares of common stock are listed on Nasdaq as “TIVC,” with a last reported price of $2.99 on October 15, 2025.
Shares outstanding were 1,695,732 as of October 15, 2025; this is a baseline figure, not the amount being offered.
Tivic Health Systems (TIVC) filed an S-3 resale registration covering up to 1,580,437 shares of common stock. The registered shares consist of up to 1,352,395 shares issuable upon conversion of Series B Non‑Voting Convertible Preferred from the fourth tranche, 195,793 shares issuable upon exercise of related Investor Warrants, and 32,249 shares issuable upon exercise of Placement Agent Warrants.
The company is not selling shares in this filing and will not receive proceeds from any resale by the selling stockholders. Tivic would receive cash only if warrants are exercised, at which point the exercise price would be paid to the company. Shares may be sold by the holders on Nasdaq or in private transactions at market or negotiated prices.
Shares of TIVC trade on the Nasdaq Capital Market; the last reported sale price was $2.99 per share on October 15, 2025. As context, shares outstanding were 1,695,732 as of October 15, 2025.
FAQ
What is the current stock price of Tivic Health Systems (TIVC)?
What is the market cap of Tivic Health Systems (TIVC)?
